{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/lyme-disease/","result":{"data":{"firstChapter":{"id":"5995c194-77ea-5203-83e7-86b64985db74","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 1f54e0d7-935f-48ee-b646-43bfc9901744 --><h1>Lyme disease: Summary</h1><!-- end field 1f54e0d7-935f-48ee-b646-43bfc9901744 -->","htmlStringContent":"<!-- begin item c78592d7-c0b2-4d52-b48c-d8f4473a51c5 --><!-- begin field f6deaf52-b13e-48d9-8fa5-27d23af7eb9d --><ul><li>Lyme disease is an infection caused by a group of bacteria called <em>Borrelia burgdorferi</em>, which are transmitted to humans following a bite from an infected tick.</li><li>The true incidence of Lyme disease is unknown, however it is estimated that there are 2,000–3,000 new confirmed cases of Lyme disease each year in England and Wales.</li><li>Risk factors for Lyme disease include:<ul><li>Occupational and recreational exposure to woodland, and fields — particularly in areas with a higher incidence of infection.</li><li>Increased duration of tick attachment.</li></ul></li><li>Complications include:<ul><li>Severe neurological symptoms.</li><li>Acrodermatitis chronica atrophans.</li><li>Lyme arthritis.</li></ul></li><li>A diagnosis of Lyme disease should be made in people with erythema migrans rash, as it only occurs in Lyme disease.</li><li>People with erythema migrans and no focal symptoms should be prescribed oral antibiotics.<ul><li>People with focal symptoms should be referred to the appropriate specialist, but treatment should not be delayed.</li></ul></li><li>If Lyme disease is suspected in people without erythema migrans, an enzyme-linked immunosorbent assay (ELISA) test for Lyme disease should be offered.</li><li>If the ELISA test (in people without erythema migrans) is:<ul><li>Positive, or equivocal — an immunoblot test for Lyme disease should be performed. Starting treatment with antibiotics should be considered while waiting for the results if there is a high clinical suspicion of Lyme disease.</li><li>Negative, and the person still has symptoms — their history and symptoms should be reviewed, and an alternative diagnosis considered. If Lyme disease is still suspected in people tested within 4 weeks from symptom onset, the ELISA test should be repeated 4–6 weeks after the first ELISA test. If Lyme disease is still suspected in people who have had symptoms for 12 weeks or more, an immunoblot test should be performed.</li></ul></li><li>If the immunoblot test is:<ul><li>Positive — Lyme disease should be diagnosed and oral antibiotics started.</li><li>Negative, but symptoms persist — a discussion with or referral to a specialist (regardless of the ELISA result) should be considered.</li><li>Negative, and symptoms have resolved — no treatment is required.</li></ul></li><li>People diagnosed with Lyme disease should be prescribed oral antibiotics:<ul><li>Adults and children aged 12 years or older — doxycycline 100 mg twice daily (or 200 mg once daily) for 21 days; or amoxicillin 1000 mg three times daily for 21 days; or azithromycin 500 mg daily for 17 days.</li><li>Children aged 9–12 years — doxycycline 5 mg/kg in two divided doses on day one, followed by 2.5 mg/kg daily in one or two divided doses for a total of 21 days (for children under 45 kg); or amoxicillin 30 mg/kg three times daily for 21 days (for children 33 kg and under); or azithromycin 10 mg/kg daily for 17 days, (for children 50 kg and under).</li><li>Children aged under 9 years — amoxicillin 30 mg/kg three times daily for 21 days (for children 33 kg and under), or azithromycin — 10 mg/kg daily for 17 days (for children 50 kg and under).</li></ul></li></ul><!-- end field f6deaf52-b13e-48d9-8fa5-27d23af7eb9d --><!-- end item c78592d7-c0b2-4d52-b48c-d8f4473a51c5 -->","topic":{"id":"56ba86e1-b79d-5c00-948b-65c581b69f79","topicId":"7aa291ec-f53e-44b9-8a66-e9b4ee6a577f","topicName":"Lyme disease","slug":"lyme-disease","aliases":[],"chapters":[{"id":"5995c194-77ea-5203-83e7-86b64985db74","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"cc168196-a2da-5a8f-873c-fb75c4c3960f","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"a8622b23-7f1f-543b-b5ba-e9f4c9547c1c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"4c25a599-a26d-5702-b9f6-43dff73c83c8","slug":"changes","fullItemName":"Changes"},{"id":"29379f04-710e-5ce7-ba07-ea9a1e178ac7","slug":"update","fullItemName":"Update"}]},{"id":"bc55cfd2-4253-598a-8be1-54061ce22b6a","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"49a7229f-6129-58a8-9b6e-7471ccde1b15","slug":"goals","fullItemName":"Goals"},{"id":"ca83767e-8bdd-5ab2-b78a-c8577ab6da08","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"928ab402-0b5e-53b7-96d3-a64275903911","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5230b0a-b405-5725-9a8a-95f4a63239e1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a9b48f27-60ba-54c9-9deb-e1ce41732fc9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5cc0f690-6775-5131-a1fc-75d9efa0b535","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8bbfecb1-6cb7-511b-9697-7915788a4bff","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"1c94f9ce-3656-59d3-86ed-d515d113270a","slug":"definition","fullItemName":"Definition"},{"id":"1a4679d0-b6d3-5b97-917c-5d08de1be33b","slug":"causes","fullItemName":"Causes"},{"id":"6e585a22-8dfe-578a-99a9-1be143896b7f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e1ded21e-6325-5c18-ae0a-6b540cd28c19","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"126215ba-45c3-5bbf-ae98-2fff7bb1ed89","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5240144c-4a60-5d30-ab1e-63d4f2995a2f","slug":"complications","fullItemName":"Complications"},{"id":"a5092448-11ae-5b17-8a6b-8b6f6d5b80cf","slug":"other-tick-borne-diseases","fullItemName":"Other tick-borne diseases"}]},{"id":"d2ae2f81-2546-5ff8-8002-577ff4741f57","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"0cf6a4b7-b848-5424-b311-ae2e70bf1cf4","slug":"when-to-suspect-lyme-disease","fullItemName":"When to suspect Lyme disease"},{"id":"868a26b1-1742-50d5-8576-14ab327a0c64","slug":"differential-diagnosis-erythema-migrans","fullItemName":"Differential diagnosis (erythema migrans)"}]},{"id":"1a2edd0e-8cc2-5cce-aa6f-5519b5f40775","slug":"management","fullItemName":"Management","subChapters":[{"id":"35e8dbb5-da7f-5fd3-9ff3-b9926f24ed6e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"8d378757-a1b8-5c8c-95b4-d1428557dcb3","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"10094473-f953-57de-8453-10fc5a4709a2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"714c78fe-f533-5abf-8ab9-28bdb2658044","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"245cb0af-f052-5aa2-8912-6e553063438e","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"98b0aa55-4436-555a-bfde-05ef12f03083","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"0edcddd4-56b7-5124-b56a-14f7a38f3fd5","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"d42dec32-1352-5fb5-8d7d-c3591bae0448","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"254e7467-a025-51bb-849c-803edae01e3b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"659f6620-1672-5b1d-bf3e-891ce69b4ff1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fdc13e77-5b9e-59a9-b651-15a5e1b1f333","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ccedf4e2-7c6a-5251-abee-5f5f14e5ed39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a2095079-fcfd-5a3f-85e9-d631c57dd891","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"56ba86e1-b79d-5c00-948b-65c581b69f79","topicId":"7aa291ec-f53e-44b9-8a66-e9b4ee6a577f","topicName":"Lyme disease","slug":"lyme-disease","aliases":[],"topicSummary":"Lyme disease is an infection caused by bacteria called Borrelia burgdorferi, which are transmitted to humans following a bite from an infected tick.","lastRevised":"Last revised in August 2019","nextPlannedReviewBy":"2023-08-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2023-07","nextPlannedReviewByDisplay":"July 2023","specialities":[{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"},{"id":"f8332083-731e-50fe-a895-030315ce6083","name":"Musculoskeletal","slug":"musculoskeletal"},{"id":"08590215-7450-5fd4-bb09-b98865ce23ee","name":"Neurological","slug":"neurological"},{"id":"50071c38-ab10-5ab8-ac70-6bd19a96c24e","name":"Skin and nail","slug":"skin-nail"}],"chapters":[{"id":"5995c194-77ea-5203-83e7-86b64985db74","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"cc168196-a2da-5a8f-873c-fb75c4c3960f","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"a8622b23-7f1f-543b-b5ba-e9f4c9547c1c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"4c25a599-a26d-5702-b9f6-43dff73c83c8","slug":"changes","fullItemName":"Changes"},{"id":"29379f04-710e-5ce7-ba07-ea9a1e178ac7","slug":"update","fullItemName":"Update"}]},{"id":"bc55cfd2-4253-598a-8be1-54061ce22b6a","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"49a7229f-6129-58a8-9b6e-7471ccde1b15","slug":"goals","fullItemName":"Goals"},{"id":"ca83767e-8bdd-5ab2-b78a-c8577ab6da08","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"928ab402-0b5e-53b7-96d3-a64275903911","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"d5230b0a-b405-5725-9a8a-95f4a63239e1","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a9b48f27-60ba-54c9-9deb-e1ce41732fc9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"5cc0f690-6775-5131-a1fc-75d9efa0b535","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"8bbfecb1-6cb7-511b-9697-7915788a4bff","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"1c94f9ce-3656-59d3-86ed-d515d113270a","slug":"definition","fullItemName":"Definition"},{"id":"1a4679d0-b6d3-5b97-917c-5d08de1be33b","slug":"causes","fullItemName":"Causes"},{"id":"6e585a22-8dfe-578a-99a9-1be143896b7f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e1ded21e-6325-5c18-ae0a-6b540cd28c19","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"126215ba-45c3-5bbf-ae98-2fff7bb1ed89","slug":"prognosis","fullItemName":"Prognosis"},{"id":"5240144c-4a60-5d30-ab1e-63d4f2995a2f","slug":"complications","fullItemName":"Complications"},{"id":"a5092448-11ae-5b17-8a6b-8b6f6d5b80cf","slug":"other-tick-borne-diseases","fullItemName":"Other tick-borne diseases"}]},{"id":"d2ae2f81-2546-5ff8-8002-577ff4741f57","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"0cf6a4b7-b848-5424-b311-ae2e70bf1cf4","slug":"when-to-suspect-lyme-disease","fullItemName":"When to suspect Lyme disease"},{"id":"868a26b1-1742-50d5-8576-14ab327a0c64","slug":"differential-diagnosis-erythema-migrans","fullItemName":"Differential diagnosis (erythema migrans)"}]},{"id":"1a2edd0e-8cc2-5cce-aa6f-5519b5f40775","slug":"management","fullItemName":"Management","subChapters":[{"id":"35e8dbb5-da7f-5fd3-9ff3-b9926f24ed6e","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"8d378757-a1b8-5c8c-95b4-d1428557dcb3","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"10094473-f953-57de-8453-10fc5a4709a2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"714c78fe-f533-5abf-8ab9-28bdb2658044","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"245cb0af-f052-5aa2-8912-6e553063438e","slug":"azithromycin","fullItemName":"Azithromycin"}]},{"id":"98b0aa55-4436-555a-bfde-05ef12f03083","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"0edcddd4-56b7-5124-b56a-14f7a38f3fd5","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"d42dec32-1352-5fb5-8d7d-c3591bae0448","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"254e7467-a025-51bb-849c-803edae01e3b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"659f6620-1672-5b1d-bf3e-891ce69b4ff1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fdc13e77-5b9e-59a9-b651-15a5e1b1f333","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ccedf4e2-7c6a-5251-abee-5f5f14e5ed39","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"a2095079-fcfd-5a3f-85e9-d631c57dd891","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"56ba86e1-b79d-5c00-948b-65c581b69f79"}},"staticQueryHashes":["3666801979"]}